AHA 2023 Insights: Optimizing the Use of SGLT2is, GLP-1 RAs and Non-Steroidal MRAs for Multi-System Benefit

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

AHA 2023 Insights: Optimizing the Use of SGLT2is, GLP-1 RAs and Non-Steroidal MRAs for Multi-System Benefit

By AHA 2023 Insights FEATURING Faiez Zannad

1,706 views

November 21, 2023

0 Comments

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Primer on Diabetes Management

Feat. S. Inzucchi

11:37

ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich

11:25

ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster

34:49

Scripps Health

Medications for Weight Loss: The New Satiety Hormones

Feat. K. Fujioka

18:43

ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo

15:06

Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01

Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo

12:26

Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

27:14

MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz

17:44

Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24

Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan

13:07

Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

26:32

Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen

09:52

AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz

20:24

Diana Isaacs

Tirzepatide for Type 2 Diabetes

26:49

Diana Isaacs

Tirzepatide Updates

44:41

Norman Lepor

Obesity: New Understanding and Treatments

35:16

Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson

06:31

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

05:08

Susan Brian

Login

Login

Join VuMedi

AHA 2023 Insights: Optimizing the Use of SGLT2is, GLP-1 RAs and Non-Steroidal MRAs for Multi-System Benefit

Related Content